SHAMLOO (STANDFORD UNIVERSITY) - MCSP-EXPLORATORY CHEMISTRY (EC)

SHAMLOO（斯坦福大学）- MCSP-探索化学（EC）

• 批准号: 10938120
• 负责人: KEITH BARNES
• 金额: $ 126.2万
• 依托单位: ALBANY MOLECULAR RESEARCH, INC.
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-06 至 2024-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10938120
• 关键词: Academia; Basic Science; Biotechnology; Chemistry; Clinic; Clinical Trials; Data; Development; Drug Formulations; Drug Kinetics; Funding; Goals; Grant; Human; Institution; Intellectual Property; Lead; Licensing; Nervous System; Neurosciences Research; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phase; Phase I Clinical Trials; Property Rights; Research; Research Personnel; Research Support; Risk; Testing; Toxicology; Translating; United States National Institutes of Health; Universities; clinical candidate; drug development; drug discovery; experience; manufacture; nervous system disorder; novel; novel therapeutics; programs; research clinical testing; small molecule; success

SHAMLOO (STANDFORD UNIVERSITY) - MCSP-EXPLORATORY CHEMISTRY (EC) The NIH Blueprint Neurotherapeutics Network (BPN) is part of NIH Blueprint for Neuroscience Research, a collaborative framework that includes the NIH Office of the Director together with eleven NIH Institutes and Centers, that support research on the nervous system. The BPN was launched to enable neuroscientists in academia and biotechnology companies to develop new drugs for nervous system disorders. The BPN provides non-dilutive funding for small molecule drug discovery and development, from hit-to-lead chemistry through phase I clinical testing. Through the BPN program, investigators together with the NIH build a team and leverage drug discovery and development experts who can help them advance their basic research into human testing. This is accomplished through a combination of grant funding and access to a full range of NIH-funded drug discovery development CROs (medicinal chemistry, pharmacokinetics/ADME, toxicology, drug manufacturing, drug formulation and phase I clinical trials) and, most importantly, access to NIH funded consultants with extensive pharma experience spanning all drug development stages to help guide the team. A fundamental hallmark of the program is that the research institution retains the intellectual property rights. With a strong track record of success, the BPN program provides an excellent opportunity to translate basic and applied findings into novel clinical candidates and advance them to the clinic. The goal is to generate the required data to de-risk further funding for subsequent clinical trials, partnership, or out-licensing.

Shamloo（Standford University） - MCSP-探索化学（EC）NIH蓝图神经疗法网络（BPN）是NIH神经科学研究的NIH蓝图的一部分，这是一个合作框架，其中包括导演的NIH办公室，其中包括董事与Eleeven NIH Institutes and Centers and Centertes and Centers and Chore nih Institutes and Chere Research in Cranis Cranis System。 BPN的启动是为了使学术界和生物技术公司的神经科学家能够开发出用于神经系统疾病的新药。 BPN为小分子药物发现和发育提供了非二链资金，从命中至铅化学到I期临床测试。通过BPN计划，研究人员与NIH一起建立了一个团队，并利用可以帮助他们将基础研究推进人类测试的药物发现和开发专家。这是通过拨款资金和获得全面NIH资助的药物发现开发CRO（药物化学，药代动力学/ADME，毒理学，药物制造，药物制造和I期临床试验的）的结合而实现的，最重要的是，最重要的是，拥有大量药物开发阶段的NIH资助顾问，以帮助所有药物开发阶段，以帮助所有的药物指南。该计划的基本标志是研究机构保留了知识产权。 BPN计划凭借成功的成功记录，提供了一个绝佳的机会，可以将基本和应用的发现转化为新的临床候选者，并将其推进到诊所。目的是生成所需的数据，以降低风险的进一步资金，以进行随后的临床试验，合作伙伴关系或外部许可。